Special Law on Strategic Investment

Showing 4081 articles
Business

CSL's 34% Plunge: A Buying Opportunity or a Value Trap?

After a bruising year that saw its shares tumble by a third, biotech giant CSL is back in the spotlight. We delve beyond the headline numbers, examining valuation models and market sentiment to assess if the sell-off has created a compelling entry point for long-term investors.

Business

Gap's Stock Surge: Is the Turnaround Story Already Priced In?

Gap's shares have soared over 100% in three years, fueled by a remarkable operational turnaround. But as the stock hovers near $28, investors are asking: does the current price fairly reflect the future, or has the market run ahead of itself? A deep dive into valuation metrics reveals a mixed picture.